Artificial intelligence (AI) has already become part of everyday life, and it is beginning to reshape the biopharma industry. Its potential is undeniable: accelerating drug discovery, optimizing manufacturing, and bringing therapies to patients faster. Yet readiness remains low—only 14% of large biopharma companies and 3% of smaller ones are prepared to adopt AI, according to Benchling.
Artificial Intelligence Roadblocks in Pharma
For big pharma, the challenge is complexity. Years of using multiple disconnected digital tools have created data silos, inefficiencies, and IT bottlenecks. For smaller biotech companies, the issue is more basic: many are still building their digital foundations, making AI adoption feel premature.
Across the board, one obstacle persists: the disconnect between the wet lab and the dry lab. AI thrives on integrated, high-quality data. Without alignment between experimental results and computational analysis, progress stalls.
How CDMOs Can Unlock Artificial Intelligence
This is where Contract Development and Manufacturing Organizations (CDMOs) have a unique advantage. Positioned at the crossroads of biotech and pharma, CDMOs not only produce but also partner closely with clients at every stage of development. Their mission is not just to manufacture, but to manufacture smarter—faster, with stronger data integration, and with better-informed decisions.
By adopting interoperable platforms, embracing SaaS, and investing in data standards, CDMOs can help bridge the gap between science and technology. This creates an ecosystem where AI becomes a practical enabler rather than a distant promise.
Looking ahead
AI is not a luxury or a passing trend. It is an essential tool to tackle the challenges of modern medicine: complex diseases, fast-paced development timelines, personalization needs, and growing regulatory demands. The future belongs to those who can integrate AI not as a side tool, but as a core part of their operations.
But success will require more than infrastructure and software. It demands mindset, culture, and leadership. The change will not happen overnight. However, with collaboration, shared knowledge, and patient-centered focus, AI can become the bridge that transforms today’s biopharma into tomorrow’s healthcare.
So the question remains: are you ready to cross it?
About 53Biologics:
53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.
For more information or to speak with one of our experts, fill out our contact form or email us at in**@53*********.com.
